Gilead and Merck HIV Treatment Succeeds in Phase 3 Trials

In a move that advances innovation within the healthcare sector, Gilead Sciences and Merck have announced the success of Phase 3 trials ISLEND-1 and ISLEND-2 for a new once-weekly oral HIV treatment. The investigational regimen, combining islatravir and lenacapavir, successfully met its primary efficacy endpoints according to clinical reports. Furthermore, the treatment demonstrated a safety profile comparable to existing therapies with no new safety concerns identified, and both companies plan to submit the data to global regulatory authorities shortly.

This collaboration comes as the biopharmaceutical industry sees intense competition to develop long-acting treatments aimed at reducing patient pill burden. In comparison to peers, GSK (GlaxoSmithKline) reported robust sales for its long-acting HIV portfolio in recent quarters, placing pressure on Gilead and Merck to capture market share per market data. This clinical milestone is a critical pillar for supporting future revenue growth in the multi-billion dollar global HIV treatment market.

Regarding market performance, GILD shares stood at $125.5 while MRK closed at $119.6 (close June 9, 2026). Investors are now monitoring the timeline for regulatory filings with the FDA as a primary catalyst for both stocks. Looking at the economic calendar, broader healthcare sector sentiment may be influenced by the upcoming U.S. Non Farm Payrolls data, which often impacts capital flows into defensive equity positions.